Stimulation of Erythrocyte Phosphatidylserine Exposure by Paclitaxel
Open Access
- 1 January 2006
- journal article
- clinical trial
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 18 (1-3), 151-164
- https://doi.org/10.1159/000095190
Abstract
Side effects of cytostatic treatment include development of anemia resulting from either decreased generation or accelerated clearance of circulating erythrocytes. Recent experiments revealed a novel kind of stress-induced erythrocyte death, i.e. eryptosis, which is characterized by enhanced cytosolic Ca2+ levels, increased ceramide formation and exposure of phosphatidylserine at the cell surface. The present study explored whether cytostatic treatment with paclitaxel (Taxol®) triggers eryptosis. Blood was drawn from cancer patients before and after infusion of 175 mg/m2 Taxol®. The treatment significantly decreased the hematocrit and significantly increased the percentage of annexin-Vbinding erythrocytes in vivo (by 37%). In vitro incubation of human erythrocytes with 10 μM paclitaxel again significantly increased annexin-V-binding (by 129%) and augmented the increase of annexin-Vbinding following cellular stress. The enhanced phosphatidylserine exposure was not dependent on caspase-activity but paralleled by erythrocyte shrinkage, increase of cytosolic Ca2+ activity, ceramide formation and activation of calpain. Phosphatidylserine exposure was similarly induced by docetaxel but not by carboplatin or doxorubicin. Moreover, eryptosis was triggered by the Ca2+ ionophore ionomycin (10 μM). In mice, ionomycintreated eryptotic erythrocytes were rapidly cleared from circulating blood and sequestrated into the spleen. In conclusion, our data strongly suggest that paclitaxel-induced anemia is at least partially due to induction of eryptosis.Keywords
This publication has 53 references indexed in Scilit:
- The Seco-Taxane IDN5390 Is Able to Target Class III β-Tubulin and to Overcome Paclitaxel ResistanceCancer Research, 2005
- Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein BimCell Death & Differentiation, 2005
- Taxol Induces Caspase-10-dependent ApoptosisJournal of Biological Chemistry, 2004
- Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors?Nature Reviews Cancer, 2004
- Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loopOncogene, 2003
- Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independentCell Death & Differentiation, 2002
- A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanesInternational Journal of Cancer, 2001
- Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3Blood, 2001
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996